Zealand Pharma A/S (ZEAL) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.070x

Based on the latest financial reports, Zealand Pharma A/S (ZEAL) has a cash flow conversion efficiency ratio of -0.070x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Dkr-1.04 Billion ≈ $-163.16 Million USD) by net assets (Dkr14.83 Billion ≈ $2.32 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Zealand Pharma A/S (ZEAL) net asset quality to measure how much of total assets are equity-financed.

Zealand Pharma A/S - Cash Flow Conversion Efficiency Trend (2007–2025)

This chart illustrates how Zealand Pharma A/S's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Zealand Pharma A/S cash earnings quality to evaluate the quality of earnings relative to operating cash generation.

Zealand Pharma A/S Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Zealand Pharma A/S ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Advance Auto Parts Inc
NYSE:AAP
-0.009x
Viking Therapeutics Inc
NASDAQ:VKTX
-0.133x
Jiangsu Yangnong Chemical Co Ltd
SHG:600486
0.034x
Highwoods Properties Inc
NYSE:HIW
0.024x
Marriot Vacations Worldwide
NYSE:VAC
-0.002x
AllianceBernstein Holding L.P.
NYSE:AB
0.061x
Avista Corporation
NYSE:AVA
0.064x
National Storage Affiliates Trust
NYSE:NSA
0.063x

Annual Cash Flow Conversion Efficiency for Zealand Pharma A/S (2007–2025)

The table below shows the annual cash flow conversion efficiency of Zealand Pharma A/S from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see ZEAL market cap overview.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 Dkr14.83 Billion
≈ $2.32 Billion
Dkr6.53 Billion
≈ $1.02 Billion
0.440x +507.72%
2024-12-31 Dkr8.62 Billion
≈ $1.35 Billion
Dkr-930.82 Million
≈ $-145.63 Million
-0.108x +59.58%
2023-12-31 Dkr1.59 Billion
≈ $249.21 Million
Dkr-425.67 Million
≈ $-66.60 Million
-0.267x +76.86%
2022-12-31 Dkr815.91 Million
≈ $127.66 Million
Dkr-942.21 Million
≈ $-147.42 Million
-1.155x +11.60%
2021-12-31 Dkr927.80 Million
≈ $145.16 Million
Dkr-1.21 Billion
≈ $-189.62 Million
-1.306x -123.26%
2020-12-31 Dkr1.18 Billion
≈ $184.16 Million
Dkr-688.72 Million
≈ $-107.75 Million
-0.585x -77.57%
2019-12-31 Dkr1.24 Billion
≈ $194.43 Million
Dkr-409.45 Million
≈ $-64.06 Million
-0.329x +20.11%
2018-12-31 Dkr1.12 Billion
≈ $174.65 Million
Dkr-460.40 Million
≈ $-72.03 Million
-0.412x +21.81%
2017-12-31 Dkr528.47 Million
≈ $82.68 Million
Dkr-278.75 Million
≈ $-43.61 Million
-0.527x -458.73%
2016-12-31 Dkr278.19 Million
≈ $43.53 Million
Dkr40.90 Million
≈ $6.40 Million
0.147x +116.45%
2015-12-31 Dkr252.23 Million
≈ $39.46 Million
Dkr-225.41 Million
≈ $-35.27 Million
-0.894x -435.63%
2014-12-31 Dkr252.83 Million
≈ $39.56 Million
Dkr-42.18 Million
≈ $-6.60 Million
-0.167x +68.90%
2013-12-31 Dkr316.14 Million
≈ $49.46 Million
Dkr-169.62 Million
≈ $-26.54 Million
-0.537x -484.38%
2012-12-31 Dkr491.01 Million
≈ $76.82 Million
Dkr68.54 Million
≈ $10.72 Million
0.140x +3511.47%
2011-12-31 Dkr441.40 Million
≈ $69.06 Million
Dkr-1.81 Million
≈ $-282.56K
-0.004x +97.02%
2010-12-31 Dkr407.11 Million
≈ $63.70 Million
Dkr-55.98 Million
≈ $-8.76 Million
-0.138x +70.26%
2009-12-31 Dkr132.92 Million
≈ $20.80 Million
Dkr-61.45 Million
≈ $-9.61 Million
-0.462x -237.00%
2008-12-31 Dkr208.63 Million
≈ $32.64 Million
Dkr-28.62 Million
≈ $-4.48 Million
-0.137x +42.25%
2007-12-31 Dkr242.37 Million
≈ $37.92 Million
Dkr-57.57 Million
≈ $-9.01 Million
-0.238x --

About Zealand Pharma A/S

CO:ZEAL Denmark Biotechnology
Market Cap
$3.35 Billion
Dkr21.41 Billion DKK
Market Cap Rank
#4531 Global
#29 in Denmark
Share Price
Dkr304.00
Change (1 day)
-0.30%
52-Week Range
Dkr234.90 - Dkr545.80
All Time High
Dkr954.00
About

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treat… Read more